Sugi Predict

Sugi Predict / Compounds / SCHEMBL3875741

SCHEMBL3875741

SCHEMBL3875741

CC1CCCN1C(C)c1ccc(CCNC(=O)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 4/20 0.51
▸ CHRM4 P08173 1/20 0.46
▸ MCHR1 Q99705 5/20 0.46
▸ CYP2D6 P10635 3/20 0.45
▸ CHRM1 P11229 3/20 0.45
▸ HTR2A P28223 3/20 0.45
▸ HDAC4 P56524 1/20 0.45
▸ TGM2 P21980 1/20 0.45
▸ CD274 Q9NZQ7 1/20 0.45
▸ NAMPT P43490 1/20 0.44
▸ GCGR P47871 1/20 0.44
▸ DPP4 P27487 1/20 0.43
▸ ROCK2 O75116 1/20 0.43
▸ ROCK1 Q13464 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3873978 0.91 MCHR1 (0.58) HRH3CHRM4MCHR1CYP2D6CHRM1
SCHEMBL3874079 0.89 OPRM1 (0.51) HRH3CHRM4MCHR1CHRM1GCGR
SCHEMBL3869698 0.89 MCHR1 (0.59) HRH3MCHR1CYP2D6CHRM1HTR2A
SCHEMBL3868746 0.87 KDM4E (0.51) HRH3MCHR1CYP2D6CHRM1HTR2A
SCHEMBL3873309 0.84 MCHR1 (0.53) CHRM4MCHR1CYP2D6CHRM1HTR2A
SCHEMBL3879069 0.84 HRH3 (0.46) HRH3ALDH1A1
SCHEMBL3870597 0.84 MCHR1 (0.53) CHRM4MCHR1CYP2D6CHRM1HTR2A
SCHEMBL3872342 0.84 MCHR1 (0.53) CHRM4MCHR1CYP2D6CHRM1HTR2A
SCHEMBL3873176 0.82 HRH3 (0.45) HRH3MCHR1CYP2D6CHRM1HTR2A
SCHEMBL3879127 0.81 HRH3 (0.48) HRH3CHRM4CHRM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 — — US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R HRH3 64/4885CHRM4 757/4885MCHR1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.